

We Claim:

1. (original) A pharmaceutical composition comprising a tailored α_1 -adrenoceptor antagonist, a bladder-selective antagonist and optionally included 5α -reductase inhibitor, optionally together with pharmaceutically acceptable carriers, excipients or diluents.

2. (original) The pharmaceutical composition according to claim 1 wherein the tailored α_1 AR antagonist is selective for α_{1a} over α_{1b} subtype but non-selective for α_{1a} over α_{1d} subtype.

3. (original) The pharmaceutical composition according to claim 1 wherein the tailored α_1 AR antagonist is more than about 10 fold selective for α_{1a} over α_{1b} subtype and is less than about 10 fold selective for α_{1a} over α_{1d} subtype in receptor binding and *in vitro* functional assay.

4. (currently amended) The pharmaceutical composition according to claim 3 wherein the tailored α_1 adrenoceptor antagonist is selected from:

1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione,

2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione,

5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide,

1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione hydrochloride salt,

2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride salt and

5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide

hydrochloride salt,

and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomer, racemate, polymorphs, N- oxides or metabolites.

5. (cancelled)

6.5. (currently amended) The pharmaceutical composition according to claim 1, wherein the bladder selective antagonist is an agent which exhibits greater potency in inhibiting the carbachol-induced response on the bladder than the carbachol-evoked salivation when evaluated simultaneously in *in vivo* model in rabbit or dog.

~~7.~~ 6. (currently amended) The pharmaceutical composition according to claim 65
 wherein the bladder- selective antagonist is selected from:

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)phenyl acetamide,

N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl acetamide,

N-[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate,

N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

- 34 (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
 35 hydroxy-2-phenyl acetamide, ~~and~~
- 36 (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
 37 hydroxy-2-phenyl acetamide, ~~and~~
- 38 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
 39 cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt,
- 40 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl
 41 acetate L-(+)-tartrate salt,
- 42 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-
 43 phenyl acetate L-(+)-tartrate salt,
- 44 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-
 45 phenyl acetate L-(+)-tartrate salt,
- 46 (2R)-(+)- (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-
 47 hydroxy-2-cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt,
- 48 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
 49 cyclopentyl-2-phenyl acetamide hydrochloride salt,
- 50 (2R)- (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
 51 cyclopentyl-2-phenyl acetamide hydrochloride salt,
- 52 (2S)-(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
 53 cyclopentyl-2-phenyl acetamide hydrochloride salt,
- 54 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-
 55 difluorocyclopentyl)-2-phenyl acetamide tartrate salt,
- 56 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-
 57 diphenyl acetamide
- 58 N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)
 59 phenyl acetamide tartrate salt,
- 60 (2R, 2S)-N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-
 61 phenyl acetamide hydrochloride salt,
- 62 N-[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6ylmethyl]-2-cyclopentyl-2-hydroxy-2-
 63 phenyl acetamide hydrochloride salt,
- 64 (2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-
 65 3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,
- 66 (2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1S or 1R)-
 67 3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,
- 68 (2R, 2S)- (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-
 69 hydroxy-2-cyclohexyl-2-phenyl acetamide succinate salt,

(2R, 2S)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide tartrate salt,
(2R, 2S)-(1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,
(2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,
(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide tartrate salt,
2R(+),4[(1R, 5S)-3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate hydrochloride,
N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,
(2R) (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,
(2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide succinate salt,
(2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,
(1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline carboxylate,
(1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline carboxylate succinate salt,
2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester and
2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester with (2E)-2-butenedioate and
their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs, N-oxide or metabolites.

8. (cancelled).

~~9.7.~~ (currently amended) The pharmaceutical composition according to claim 1 wherein said 5 α -reductase inhibitor is a type 1 or a type 2 or both a type 1 and type 2 or a dual type 1 and type 2 inhibitor.

~~10.8.~~ (currently amended) The pharmaceutical composition according to claim ~~9~~ 7 wherein the 5 α -reductase inhibitor is a dual type 1 and type 2 inhibitor.

1 ~~11.~~ 9. (currently amended) The pharmaceutical composition according to claim ~~10~~ 8
2 wherein the dual type 1 and type 2 inhibitor is dutasteride.

1 ~~12.~~ 10. (currently amended) The pharmaceutical composition according to claim ~~9~~ 7
2 wherein the 5 α -reductase inhibitor is a type 2 inhibitor.

1 ~~13.~~ 11. (currently amended) The pharmaceutical composition according to claim ~~12~~ 10
2 wherein the type 2 inhibitor is finasteride.

1 ~~14.~~ 12. (currently amended) A pharmaceutical product or medicament comprising a
2 first pharmaceutical composition of a tailored α_1 adrenoceptor antagonist, a second
3 pharmaceutical composition of a bladder selective antagonist and optionally included a third
4 pharmaceutical composition of 5 α -reductase inhibitor.

1 ~~15.~~ 13. (currently amended) A pharmaceutical product or medicament of claim ~~14~~ 12
2 wherein the product or medicament is a combined preparation.

1 ~~16.~~ 14. (currently amended) A pharmaceutical product or medicament according to
2 claim ~~15~~ 13 wherein the combined preparation is single dosage form.

1 ~~17.~~ 15. (currently amended) A pharmaceutical product or medicament according to
2 claim ~~15~~ 13 wherein the combined preparation comprises separate dosage forms.

1 ~~18.~~ 16. (currently amended) A pharmaceutical product or medicament according to
2 claim ~~14~~ 12 wherein the tailored α_1 AR antagonist is selective for α_{1a} over α_{1b} subtype but
3 non-selective for α_{1a} over α_{1d} subtype.

1 ~~19.~~ 17. (currently amended) A pharmaceutical product or medicament according to
2 claim ~~14~~ 12 wherein the tailored α_1 AR antagonist is more than about 10 fold selective for α_{1a}
3 as compared to α_{1b} subtype and is less than about 10 fold selective for α_{1a} over α_{1d} subtype in
4 receptor binding and *in vitro* functional assay.

1 ~~20.~~ 18. (currently amended) The pharmaceutical product or medicament according to
2 claim ~~19~~ 17 wherein the tailored α_1 adrenoceptor antagonist is selected from:

3 1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione,

2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione,

5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide,

1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione hydrochloride salt,

2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-

1,3(2H)-dione hydrochloride salt and

5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide

hydrochloride salt,

and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomer, racemate, polymorphs, N- oxides or metabolites.

21. (cancelled).

22-19. (currently amended) A pharmaceutical product or medicament according to claim 14-12 wherein the bladder-selective antagonist is an agent which exhibits greater potency in inhibiting the carbachol-induced response on the bladder than the carbachol-evoked salivation when evaluated simultaneously in *in vivo* model in rabbit or dog.

23-20. (currently amended) A pharmaceutical product or medicament according to claim 22 19 wherein the bladder-selective antagonist is selected from:

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]-hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

- 17 N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)
18 phenyl acetamide,
- 19 N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]-hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl
20 acetamide,
- 21 N-[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6ylmethyl]-2-cyclopentyl-2-hydroxy-2-
22 phenyl acetamide,
- 23 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-
24 difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide,
- 25 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
26 cyclohexyl-2-phenyl acetamide,
- 27 (1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-
28 cyclopentyl-2-phenyl acetamide,
- 29 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-
30 diphenyl acetamide,
- 31 3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate,
- 32 N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hex-6-yl]-2-
33 cyclopentyl-2-hydroxy-2-phenyl acetamide,
- 34 (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-
35 cyclopentyl-2-hydroxy-2-phenyl acetamide,
- 36 (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
37 hydroxy-2-phenyl acetamide, ~~and~~
- 38 (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
39 hydroxy-2-phenyl acetamide, ~~and~~
- 40 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
41 cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt,
- 42 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl
43 acetate L-(+)-tartrate salt,
- 44 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-
45 phenyl acetate L-(+)-tartrate salt,
- 46 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]-hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-
47 phenyl acetate L-(+)-tartrate salt,
- 48 (2R)-(+)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-
49 hydroxy-2-cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt,
- 50 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
51 cyclopentyl-2-phenyl acetamide hydrochloride salt,
- 52 (2R)-(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
53 cyclopentyl-2-phenyl acetamide hydrochloride salt,

- 54 (2S)-(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
 55 cyclopentyl-2-phenyl acetamide hydrochloride salt,
- 56 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-
 57 difluorocyclopentyl)-2-phenyl acetamide tartrate salt,
- 58 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-
 59 diphenyl acetamide
- 60 N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)
 61 phenyl acetamide tartrate salt,
- 62 (2R, 2S)-N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]-hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-
 63 phenyl acetamide hydrochloride salt,
- 64 N-[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6ylmethyl]-2-cyclopentyl-2-hydroxy-2-
 65 phenyl acetamide hydrochloride salt,
- 66 (2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-
 67 3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,
- 68 (2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1S or 1R)-
 69 3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,
- 70 (2R, 2S)- (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-
 71 hydroxy-2-cyclohexyl-2-phenyl acetamide succinate salt,
- 72 (2R, 2S)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-
 73 2-cyclohexyl-2-phenyl acetamide tartrate salt,
- 74 (2R, 2S)-(1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-
 75 hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,
- 76 (2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
 77 cyclopentyl-2-phenyl acetamide tartrate salt,
- 78 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-
 79 diphenyl acetamide tartrate salt,
- 80 2R(+),4[(1R, 5S)-3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl
 81 acetate hydrochloride,
- 82 N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hex-6-yl]-2-
 83 cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,
- 84 (2R) (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-
 85 cyclopentyl-2-hydroxy-2-phenyl acetamide,
- 86 (2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
 87 hydroxy-2-phenyl acetamide succinate salt,
- 88 (2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
 89 hydroxy-2-phenyl acetamide L(+)-tartrate salt,
- 90 (1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline
 91 carboxylate,

92 (1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline
 93 carboxylate succinate salt,
 94 2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-
 95 (hydroxymethyl)phenyl ester and
 96 2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-
 97 (hydroxymethyl)phenyl ester with (2E)-2-butenedioate.
 1 their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers,
 2 diastereomers, polymorphs, N-oxide or metabolites.

3 24. (cancelled).

1 ~~25.~~21. (currently amended) A pharmaceutical product or medicament according to
 2 claim 14 12 wherein the 5 α -reductase inhibitor is a type 1 or a type 2 or both a type 1 and
 3 type 2 or a dual type 1 and type 2 inhibitor.

1 26. (cancelled).

1 ~~27.~~22. (currently amended) A pharmaceutical product or medicament according to
 2 claim 26 wherein the dual type 1 and type 2 inhibitor is dutasteride.

1 28. (cancelled).

1 ~~29.~~23. (currently amended) A product or medicament according to claim ~~28~~ 21
 2 wherein the type 2 inhibitor is finasteride.

1 ~~30.~~24. (currently amended) method for treatment of a mammal suffering from lower
 2 urinary tract symptoms (LUTS) associated with or without BPH, comprising administering to
 3 said mammal, a therapeutically effective amount of a product or medicament, comprising a
 4 tailored α_1 AR antagonist, a bladder-selective antagonist and optionally included 5 α -reductase
 5 inhibitor.

1 31. (cancelled).

1 32. (cancelled).

1 ~~33.~~25. (currently amended) The method according to claim ~~32~~ 24 wherein the
 2 mammal is a human male.

1 ~~34.~~26. (currently amended) The method according to claim ~~32~~ 24 wherein the
 2 mammal is a human female.

35. (cancelled).

36. (cancelled)

37. (cancelled).

39. (cancelled).

40. (cancelled).

~~41.~~ 27. (currently amended) The method according to claim ~~30~~ 24 wherein the tailored α_1 AR antagonist is selective for α_{1a} over α_{1b} subtype but non-selective for α_{1a} over α_{1d} subtype AR antagonist.

~~42.~~ 28. (currently amended) The method according to claim ~~30~~ 24 wherein the tailored α_1 AR antagonist is more than about 10 fold selective for α_{1a} as compared to α_{1b} subtype and is less than about 10 fold selective for α_{1a} as compared to α_{1d} subtype in receptor binding and functional assay.

~~43.~~ 29. (currently amended) The method according to claim ~~42~~ 28 wherein the tailored α_1 AR antagonist is selected from:

1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione,
 2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione,
 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide,
1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione hydrochloride salt,
2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride salt and
5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide hydrochloride salt,

and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomer, racemate, polymorphs, N- oxides or metabolites.

44. (cancelled).

~~45.~~ 30. (currently amended) The method according to claim ~~30~~ 24 wherein the bladder-selective antagonist is an agent which exhibits greater potency in inhibiting the carbachol-induced response on the bladder than the carbachol-evoked salivation when evaluated simultaneously in *in vivo* model in rabbit or dog.

~~46.31.~~ (currently amended) The method according to claim ~~45~~ 30 wherein the bladder-selective antagonist is selected from:

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenyl acetamide,

N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl acetamide,

N-{[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6-ylmethyl]}-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate,

N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide, and

(1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide, and

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L(+)-tartrate salt,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate L(+)-tartrate salt,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate L(+)-tartrate salt,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate L(+)-tartrate salt,

(2R)-(+)- (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L(+)-tartrate salt,

(2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2R)- (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2S)-(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide tartrate salt,

(2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenyl acetamide tartrate salt,

(2R, 2S)-N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl acetamide hydrochloride salt,

N-[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide hydrochloride salt,

(2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

(2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1S or 1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

(2R, 2S)- (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide succinate salt,

(2R, 2S)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide tartrate salt,

(2R, 2S)-(1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,

(2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide tartrate salt,

2R(+),4[(1R, 5S)-3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate hydrochloride,

N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,

(2R) (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide succinate salt,

(2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,

(1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate,

(1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate succinate salt,

2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester and

2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester with (2E)-2-butenedioate.

their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs, N-oxides or metabolites.

47. (cancelled).

48. (cancelled).

49. (cancelled).

50. (cancelled).

51. (cancelled).

52. (cancelled).